Last reviewed · How we verify

monoclonal antibodies GD2

Federal Research Institute of Pediatric Hematology, Oncology and Immunology · Phase 3 active Small molecule

monoclonal antibodies GD2 is a Monoclonal antibody Small molecule drug developed by Federal Research Institute of Pediatric Hematology, Oncology and Immunology. It is currently in Phase 3 development for Neuroblastoma.

GD2-targeting monoclonal antibodies work by binding to GD2, a glycolipid found on the surface of certain cancer cells, to induce cell death and inhibit tumor growth.

GD2-targeting monoclonal antibodies work by binding to GD2, a glycolipid found on the surface of certain cancer cells, to induce cell death and inhibit tumor growth. Used for Neuroblastoma.

At a glance

Generic namemonoclonal antibodies GD2
SponsorFederal Research Institute of Pediatric Hematology, Oncology and Immunology
Drug classMonoclonal antibody
TargetGD2
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

GD2 is a glycolipid that is overexpressed on the surface of neuroblastoma cells. By targeting GD2, GD2-targeting monoclonal antibodies can selectively kill cancer cells while sparing normal cells. This mechanism of action is thought to be responsible for the therapeutic effects of these antibodies.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about monoclonal antibodies GD2

What is monoclonal antibodies GD2?

monoclonal antibodies GD2 is a Monoclonal antibody drug developed by Federal Research Institute of Pediatric Hematology, Oncology and Immunology, indicated for Neuroblastoma.

How does monoclonal antibodies GD2 work?

GD2-targeting monoclonal antibodies work by binding to GD2, a glycolipid found on the surface of certain cancer cells, to induce cell death and inhibit tumor growth.

What is monoclonal antibodies GD2 used for?

monoclonal antibodies GD2 is indicated for Neuroblastoma.

Who makes monoclonal antibodies GD2?

monoclonal antibodies GD2 is developed by Federal Research Institute of Pediatric Hematology, Oncology and Immunology (see full Federal Research Institute of Pediatric Hematology, Oncology and Immunology pipeline at /company/federal-research-institute-of-pediatric-hematology-oncology-and-immunology).

What drug class is monoclonal antibodies GD2 in?

monoclonal antibodies GD2 belongs to the Monoclonal antibody class. See all Monoclonal antibody drugs at /class/monoclonal-antibody.

What development phase is monoclonal antibodies GD2 in?

monoclonal antibodies GD2 is in Phase 3.

What are the side effects of monoclonal antibodies GD2?

Common side effects of monoclonal antibodies GD2 include Fatigue, Nausea, Vomiting, Diarrhea, Abdominal pain.

What does monoclonal antibodies GD2 target?

monoclonal antibodies GD2 targets GD2 and is a Monoclonal antibody.

Related